Production & Manufacturing

UNDBIO to Build $100M Insulin Manufacturing Facility in West...

UNDBIO, a South Korean pharmaceutical company focused on diabetic care, will spend $100 million to build an insulin manufacturing facility in West Virginia. The project is expected...

Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters...

Lonza announces the start of new mid-scale manufacturing assets at its API manufacturing center in Nansha, China. Commercial mid-scale operations are now underway at the...

How ‘First-Time Right’ Formulations Can Help Address the Challenge...

For years, global healthcare systems have been facing the triple threat of rising incidences of long-term conditions (LTC), aging populations and dwindling resources. At the...

By 2030, OSD Contract Manufacturing Will Be $54.7 Billion

The global oral solid dosage (OSD) contract manufacturing market is anticipated to reach $54.7 billion in value by 2030, exhibiting a compound annual growth rate...

By 2026, Pharma Contract Manufacturing To Be Worth $130bn

The global pharmaceutical contract manufacturing market is anticipated to reach $130.2 billion by 2026 as a result of increasing demand for pharmaceuticals, particularly in developing...

Leanings In The Biopharma Contract Manufacturing For 2022

A recent survey found that 86.9% of biopharmaceutical businesses outsource at least a portion of their operations, which has contributed to the $14 billion market...

FTC Aims Manufacturer, PBM Rebates For Rising Insulin Costs

Bribes and rebate arrangements involving drugmakers and pharma middlemen are all being investigated by US regulators, with a particular focus on rising insulin prices. The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read